Status:
UNKNOWN
Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis
Lead Sponsor:
Cantonal Hospital of St. Gallen
Collaborating Sponsors:
Bayer
Conditions:
Multiple Sclerosis
Cognitive Impairment
Eligibility:
All Genders
18-55 years
Brief Summary
This study is a cross sectional study of patients diagnosed with clinically isolated syndrome (CIS) and RRMS, who will undergo a series of tests to assess cognitive impairment, fatigue severity and de...
Eligibility Criteria
Inclusion
- Patients between 18 and 55 years at presentation
- Diagnosis of relapsing-remitting MS according to revised McDonald criteria 2005, clinically isolated syndrome suggestive of MS
- Patients treated with interferon-beta 1b
- Untreated patients
- EDSS under 5.5
Exclusion
- Brain pathology other than MS
- Known history of head trauma
- Pure spinal manifestation of demyelization
- Neuromyelitis optica
- Primary and secondary progressive MS
- Benzodiazepine intake within the last three months
- Relapse within the last three months
- Steroid intake within the last three months
- History of severe depressive disorder and/or suicidality, seizure, drug or alcohol abuse
- No informed consent
- Insufficient knowledge of German
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01250665
Start Date
January 1 2011
End Date
June 1 2011
Last Update
December 1 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cantonal Hospital of Saint Gallen
Sankt Gallen, Switzerland, 9007